{
    "clinical_study": {
        "@rank": "106019", 
        "arm_group": [
            {
                "arm_group_label": "30 Gy in 5 fractions of 6 Gy", 
                "arm_group_type": "Experimental", 
                "description": "tumors \u2264 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89"
            }, 
            {
                "arm_group_label": "40 Gy in 10 fractions of 4 Gy", 
                "arm_group_type": "Experimental", 
                "description": "tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96"
            }
        ], 
        "brief_summary": {
            "textblock": "Radiotherapy is a treatment considered standard for non melanoma skin cancer. This\n      institution uses schemes of 4 to 6 weeks of treatment. The objective of the study is to\n      perform radiation therapy in 1 to 2 weeks, depending on the size of the lesion."
        }, 
        "brief_title": "Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Non-melanoma Skin Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Basosquamous", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Delineation of radiation field\n\n        -  Gross tumor volume (GTV): disease clinically visible / palpable\n\n        -  clinical target volume (CTV): equal to GTV\n\n        -  planned treatment volume (PTV):\n\n        -  tumors \u2264 2 cm in diameter, with 5-10 mm CTV margin\n\n        -  tumors> 2-5 cm in diameter, with 15-20 mm CTV margin\n\n        -  Marking the GTV and PTV pen back projection\n\n        -  photograph of the treatment area\n\n        -  protections of the normal structures with blocks of lead, if necessary\n\n      Technical\n\n        -  Distance focus-skin Tube: 35 cm Locator: 30 and 40 cm\n\n        -  Sizes Tube: 2, 3 and 4 cm in diameter Finder: 6x8 cm, 8x10 cm\n\n        -  Energy:\n\n           80 kV 140 kv\n\n        -  Filter 80 kV, 2 mm Al 140 kv, 0.5 mm Copper\n\n        -  Current Draw: 20 mA\n\n      Dose\n\n        -  tumors \u2264 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a  week -\n           TDF: 89\n\n        -  tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week -\n           TDF: 96\n\n      Clinical revisions every 5 weekly sessions, or a weekly and at the end of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cosmesis not important\n\n          -  Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of any differentiation\n\n          -  Clinical stage I and II\n\n          -  Location on the thorax, abdomen, pelvis (except perineum), arm, thigh, cheek\n\n          -  Patient with up to 3 injuries eligible for the study\n\n          -  Karnofsky Performance Status (KPS) \u2265 70%\n\n          -  Age > 18 years\n\n          -  Informed Consent signed by the patient consenting to undergo the study\n\n        Exclusion Criteria:\n\n          -  Indian Race\n\n          -  Prior treatment for their skin cancer\n\n          -  More than three synchronous lesions to treatment with RT\n\n          -  Basal syndrome, xeroderma, vitiligo and albinism\n\n          -  Immunosuppression\n\n          -  Prior burn at the tumor site\n\n          -  Tumor > 5 cm\n\n          -  Age <18 years\n\n          -  Carrier mental incapacity\n\n          -  People in a relationship of dependence as prisoners, soldiers, students, staff, etc.."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080962", 
            "org_study_id": "399/2010"
        }, 
        "intervention": [
            {
                "arm_group_label": "30 Gy in 5 fractions of 6 Gy", 
                "description": "5 fractions of 600 cGy, once a day, five times a week - TDF: 89", 
                "intervention_name": "30 Gy in 5 fractions", 
                "intervention_type": "Radiation", 
                "other_name": "hypofractionated orthovoltage"
            }, 
            {
                "arm_group_label": "40 Gy in 10 fractions of 4 Gy", 
                "description": "tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96", 
                "intervention_name": "40 Gy in 10 fractions", 
                "intervention_type": "Radiation", 
                "other_name": "hypofractionated orthovoltage"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "non-melanoma skin cancer, radiotherapy, orthovoltage", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barretos", 
                    "country": "Brazil", 
                    "state": "Sao Paulo", 
                    "zip": "14784400"
                }, 
                "name": "Barretos Cancer Hospital - Fundacao Pio XII"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer: Study Phase II Clinical Trial", 
        "overall_official": {
            "affiliation": "Barretos Cancer Hospital - Funda\u00e7\u00e3o Pio XII", 
            "last_name": "Ricardo A Nakamura, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "RECIST criteria\nComplete Response: disappearance of the lesion\nPartial Response: Reduction \u2265 30% of the larger initial diameter of the lesion\nProgressive Disease: \u2265 20% increase in the largest initial diameter of the lesion\nStable disease: not increase enough to consider disease progression or reduction sufficient to consider a partial response.", 
            "measure": "Rate of complete remission with hypofractionated RT schemes for NMSC.", 
            "safety_issue": "Yes", 
            "time_frame": "Second week and twelfth week after initiation of radiotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080962"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "EORTC QLQ-C30", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Second week and twelfth week after initiation of radiotherapy"
            }, 
            {
                "description": "Late Effects of Normal Tissue (LENT) SOMA Toxicity Grading and Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Second week and twelfth week after initiation of radiotherapy"
            }
        ], 
        "source": "Barretos Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barretos Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Low rate of recruitment."
    }
}